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Available online 13 April 2016Nutrition plays a signiﬁcant role in the increasing prevalence of metabolic and brain disorders. Here we employ
systemsnutrigenomics to scrutinize the genomic bases of nutrient–host interaction underlying disease predispo-
sition or therapeutic potential. We conducted transcriptome and epigenome sequencing of hypothalamus
(metabolic control) and hippocampus (cognitive processing) from a rodent model of fructose consumption,
and identiﬁed signiﬁcant reprogramming of DNA methylation, transcript abundance, alternative splicing, and
gene networks governing cell metabolism, cell communication, inﬂammation, and neuronal signaling. These sig-
nals convergedwith genetic causal risks ofmetabolic, neurological, and psychiatric disorders revealed in humans.
Gene network modeling uncovered the extracellular matrix genes Bgn and Fmod as main orchestrators of the ef-
fects of fructose, as validated using two knockout mousemodels. We further demonstrate that an omega-3 fatty
acid, DHA, reverses the genomic and network perturbations elicited by fructose, providingmolecular support for
nutritional interventions to counteract diet-induced metabolic and brain disorders. Our integrative approach
complementing rodent and human studies supports the applicability of nutrigenomics principles to predict dis-
ease susceptibility and to guide personalized medicine.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Extracellular matrix1. Introduction
Metabolic disorders (MetDs) such as metabolic syndrome, obesity,
and type 2 diabetes (T2D) have become a pressing health apprehension
worldwide due to their increasing prevalence and high mortality rate,
and evenmore recently to their ability to escalate the pathology of neu-
rological and psychiatric disorders (Bomﬁm et al., 2012, Newcomer,
2007; Farooqui et al., 2012, Lowette et al., 2015). Among the potential
culprits for the rising epidemic of metabolic and brain disorders areeurosurgery andDepartment of
ia, Los Angeles, Los Angeles, CA
ative Biology and Physiology,
5, USA.
ez-Pinilla), xyang123@ucla.edu
. This is an open access article underdietary components introduced through industrialization (Chassaing
et al., 2015, Suez et al., 2014). In particular, fructose, which has been
widely used as a “safe and healthy” sweetener in soft drinks and proc-
essed foods in the past decades, is emerging as a signiﬁcant contributor
to MetDs in humans (Lyssiotis and Cantley, 2013, Lustig et al., 2012).
Fructose-induced MeDs has been shown to reduce hippocampal-
dependent memory (Agrawal and Gomez-Pinilla, 2012) and to worsen
the pathology of brain disorders in rodents (Agrawal et al., 2015).
Conversely, the omega-3 fatty acid docosahexaenoic acid (DHA) has
been shown to attenuate MetDs (Steffen et al., 2015, Virtanen et al.,
2014, De caterina, 2011), and to counteract the deleterious effects of
fructose on brain function and plasticity (Bremer et al., 2014, Agrawal
and Gomez-Pinilla, 2012). Our understanding of the molecular mecha-
nisms underlying the actions of fructose and DHA on MetDs and brain
disorders has been limited by conventional approaches focusing on
isolated molecular events. This limitation has delayed major advancesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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treatment of common complex disorders.
As fundamental aspects of gene regulation, disruptions in
epigenomic reprogramming, transcript abundance, alternative splicing,
and gene–gene interactions are increasingly recognized as core aspects
of wide-ranging pathogenesis (Chen et al., 2008, Zhang et al., 2013,
Rhinn et al., 2013, Narayanan et al., 2014, Makinen et al., 2014, Yang
et al., 2009). Systems nutrigenomics is emerging as a powerful ap-
proach to reveal the hidden aspects of pathogenesis under dietarymod-
ulation (Zhao et al., 2015, De Graaf et al., 2009, Panagiotou and Nielsen,
2009). Herewe apply systems nutrigenomics to unveil themultidimen-
sional molecular interactions driven by fructose and DHA that regulate
pathogenesis and recovery, and to provide proof-of-principle on the po-
tential of systems nutrigenomics to guide personalized medicine. The
comparative account of nutrigenomics signals between fructose and
DHA is crucial to understand how select diets impact the molecular
substrates governing the balance between normal brain function and
disease, and holds potential for guiding effective preventative and
therapeutic strategies to mitigate common human diseases.
2. Materials and Methods
We describe essential methods in the main text and detailed exper-
imental procedures are available in the Supplemental Materials.
2.1. Overall Study Design
As depicted in the analysis ﬂow in Fig. 1, we focus our study on two
key regions in the rodent brain that are important for the regulation of
metabolism (hypothalamus) and cognition (hippocampus), and there-
fore can play a major role in fructose-induced metabolic and brain
dysregulation aswell asDHA-mediated recovery.We analyzed the tran-
scriptome and DNA methylome using next generation sequencing,
followed by investigation of the regulatory relationship between the
methylome and transcriptome. Network approaches were then applied
to model gene–gene interactions and to predict essential perturbation
or regulatory points. Knockout mouse models were subsequently used
to validate the predicted regulatory genes with regard to their ability
tomodulatemetabolic and behavior phenotypes. To infer translatability
to human pathophysiology, we assessed the intersection of theFig. 1. Overall study design and analysis ﬂow.molecular signals from our rodent models with human genome-wide
association studies (GWAS) of metabolic and brain disorders.
2.2. Rat model of fructose consumption and DHA supplementation
Male Sprague–Dawley rats (Charles River Laboratories, Inc., MA,
USA) of 2 months old weighing 200-220 g were randomly assigned to
15% fructose treatment (n = 8, 15% w/v fructose in the drinking
water), 15% fructose plus an omega-3 fatty acid diet rich in DHA (n =
8; 0.5% of ﬂaxseed oil supplying ALA and 1.2% of DHA capsule oil, Nordic
Naturals, Inc., CA, USA), or a control group (n = 8, without fructose in
drinkingwater or DHA supplement) for sixweeks. Sample sizewas cho-
sen to yield N80% statistical power to detect 30% between-group differ-
ence with 10% within-group difference in a phenotype using two-sided
Student's t-test. The rats were singly housed in polyacrylic cages with
free access to water and their respective diets, and maintained under
standard housing conditions (room temperature 22–24 °C) with 12 h
light/dark cycle. Daily food and drink intake were monitored. The
fructose intake level is approximately equivalent to long-term
daily consumption of 130 g sugar in 1–2 l soda drinks in a 60 kg
human. The total fat content in the control and DHA diets was 10 g
per 100 g of diet. The rats were then examined for changes in MetD-
related phenotypes (serum levels of insulin, glucose, and triglycerides,
and insulin resistance index (fasting glucose [mg/dl] × fasting insulin
[ng/ml] / 16.31)). Rats were trained in the Barnes maze test for 5 days
to learn the task prior to diet treatment and then tested for memory
retention in the Barnes Maze after 6 weeks of treatment as previously
described (Agrawal and Gomez-Pinilla, 2012). Mice were sacriﬁced,
and hypothalamus and hippocampus were dissected out, ﬂash frozen,
and stored at−70 °C for transcriptome and DNAmethylome sequenc-
ing experiments.
2.3. RNA Sequencing (RNA-Seq) and Data Analyses
RNA-Seq libraries were prepared for 24 RNA samples (n = 4 per
treatment group per brain region) and sequenced in paired-end mode
by HiSeq 2000 (Illumina Inc., CA, USA) as detailed in Supplemental Ma-
terials. The short reads data were analyzed for different transcription
between treatment and control groups using the Tuxedo tool package
(Trapnell et al., 2012) and false discovery rate (FDR) was estimated
using the q-value approach. One hypothalamus sample from the
fructose group failed standard quality control and was removed from
analysis. Genes and transcripts showing differential expression or alter-
native splicing at p b 0.01 in each brain region were deﬁned as a gene
“signature” for further integrative analyses. The reliability of tran-
scriptome signals at p b 0.01 from RNA-Se1 was conﬁrmed using quan-
titative real-time PCR (qPCR) for 12 selected genes (Supplemental
Materials). Relative gene expression was represented by delta Ct =
Ctgene− CtGapdh. The RNA-Seq data was deposited to Gene Expression
Ominbus (GEO) under accession numbers GSE59918 (control and
fructose groups) and GSE 64815 (DHA).
2.4. Reduced Representation Bisulﬁte Sequencing (RRBS) of DNA
Methylome
RRBS libraries were constructed for 24 DNA samples (n = 4 per
treatment group per brain region) and sequenced using an Illumina
HiSeq 2500 System (Illumina Inc., CA, USA) as described in Supplemen-
tal Materials. Bisulﬁte-converted reads were processed using the bisul-
ﬁte aligner BS Seeker2 (Guo et al., 2013). One hypothalamus sample
from the DHA group failed standard quality control and was removed
from analysis. Differential methylation between treatment and control
groups was calculated using the R package methylKit (Akalin et al.,
2012) and FDR was estimated using the q-value approach. Loci
with methylation levels N25% between groups and FDR b 0.05 were de-
ﬁned as differentially methylated loci (DMLs). The potential cis- and
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ther examined (Supplemental Materials). RRBS data was deposited to
GEO under accession numbers GSE59893 (control and fructose groups)
and GSE64816 (DHA).
2.5. Assessing Overlap Between Fructose Signatures and Candidate Causal
Genes From Human GWAS of MetDs and Brain Disorders
We tested the consistency between the genes identiﬁed from fruc-
tose treatment in our study and those from human GWAS related to
MetDs and brain functions in two ways. First, we cross-checked genes
identiﬁed in our study with top GWAS candidate genes reported in
the GWAS catalog (http://www.genome.gov/gwastudies/) (Hindorff
et al., 2009) for direct overlap. Second, we used a SNP Set Enrichment
Analysis (SSEA) (Makinen et al., 2014), which goes beyond the top
GWAS hits and tests the overall enrichment of the genes affected in
our fructose animal model for SNPs that demonstrated disease associa-
tion in humans using Kolmogorov–Smirnov (KS) test and Fisher's exact
test. Bonferroni-corrected p b 0.05 by either KS test or Fisher's exact test
was considered signiﬁcant. The detailed methods and GWAS datasets
involved are described in Supplemental Materials.
2.6. Network Modeling and Identiﬁcation of Key Drivers (KD) of Fructose
and DHA Signatures
We obtained both protein–protein interaction (PPI) networks from
the HPRD database (http://www.hprd.org) (Keshava Prasad et al.,
2009) and tissue-speciﬁc Bayesian networks (BNs) (Zhu et al., 2004,
2008) for hypothalamus and hippocampus constructed based on genet-
ic and transcriptomic data from multiple large-scale mouse studies
(Supplemental Materials). We used the fructose or DHA signature
genes identiﬁed from the RNA-Seq analysis as seeds to extract the top
most connected subnetworks as described previously (Yang et al.,
2009). The network components including nodes and edges as well as
topological structures were visualized using Cytoscape (Smoot et al.,
2011). A Key Driver Analysis (KDA; detailed in Supplemental Materials)
(Yang et al., 2010, Zhang et al., 2013) was used to identify potential key
regulators for the fructose and DHA signatures based on the topology of
BNs and PPI networks. Brieﬂy, the neighboring subnetwork of each gene
in a given network was ﬁrst extracted and then compared with the
tissue-matched fructose or DHA signature to assess the enrichment of
genes in the latter using Fisher's exact test. Network genes that reach
Bonferroni-adjusted p b 0.05 were reported as KDs. KDs identiﬁed
from multiple networks were ranked according to a composite score
that favors KDs that are highly signiﬁcant in each KDA and are consis-
tent across network models used for KDA (Supplemental Materials).
2.7. KD Validation Using Bgn and Fmod Knockout (KO) Models
Bgn KO mice (Xu et al., 1998) and Fmod KO mice (Svensson et al.,
1999) were given as gifts from National Institute of Dental and Cranio-
facial Research and re-derived at the University of California, Los
Angeles. Mice were housed in standard polyethylene cages (3–4 mice
per cage) in an environmentally controlled room (22–24 °C) with a
12 h light/dark cycle and free access to food and water. Homozygous
male KO mice (Bgn: n = 16, Fmod: n = 11) of 9-week age were tested
againstmalewild type (WT) controls (n=8) for phenotypic changes in
metabolic (glucose tolerance, plasma lipid panel) and learning and
memory traits (Barnes maze) as described in the Supplemental
Materials.
2.8. Statistics
For metabolic and behavior phenotypes, two-sided Student's t-test
was used to test statistical differences in between fructose-treated
mice and control mice, or between the fructose and fructose + DHAgroup, or between KO mice (Bgn KO or Fmod KO) and wild-type mice.
Two-way ANOVA with Holm-Sidak post hoc analysis for multiple com-
parisons was performed for the learning curves. For RNA-Seq, RRBS,
KDA, and SSEA analyses, the statistical tests andmultiple testing correc-
tion methods were described in detail under the respective method
sections. All statistical and bioinformatics analyses were performed in
R (http://www.R-project.org/).
2.9. Study Approval
All experimentswere performed in accordancewith theNational In-
stitutes of Health Guide for the Care and Use of Laboratory Animals and
were approved by the Chancellor's Animal Research Committee of the
University of California, Los Angeles.
3. Results
3.1. Induction of Metabolic and Behavioral Abnormalities by Fructose and
Normalization by DHA
Compared to the control group (n = 8), adult rats consuming fruc-
tose (n = 8) had MetD characteristics including signiﬁcantly increased
blood glucose, triglycerides, insulin, and insulin resistance index
(Fig. 2a). The animals on fructose also displayed impaired memory as
demonstrated by prolonged latency in the Barnes Maze test (Fig. 2a).
On the other hand, fructose-treated animalswith DHA supplementation
(DHA+ fructose) showed signiﬁcantly improvedmetabolic parameters
including lower serum triglycerides, insulin, insulin resistance index,
as well as improved memory as reﬂected by the reduced latency
time in the Barnes Maze test (Fig. 2a). The measurements in the
DHA+ fructose group were not signiﬁcantly different from the control
group with no fructose treatment for triglycerides, insulin, and latency
time, indicating that DHA supplementation counteracted the fructose
effects. Of note, total caloric intake between groupswas similar between
groups.
3.2. Transcriptomic Changes in Hypothalamus and Hippocampus Induced
by Fructose and Normalization by DHA
Using RNA-Seq, we identiﬁed 581 and 146 differentially expressed
genes, 352 and 79 differentially expressed transcripts, and 99 and 53
genes showing alternative exon usage in hypothalamus and hippocam-
pus, respectively, at p b 0.01 (Dataset S1). These results support large-
scale alterations in transcriptional activities affecting both differential
expression and alternative splicing, and deﬁne 734 unique hypothalam-
ic genes (312 passed FDR b 5%) and 206 hippocampal genes (56 passed
FDR b 5%) as “fructose gene signatures”. The reliability of the differen-
tially signals at p b 0.01 was supported by consistent qPCR experiments
on 12 selected genes (Table S1). Among the signatures were transcrip-
tion factors (e.g., Aff3, Junb, Zbtb16, Tcf7l2), epigenetic regulators
(e.g., Trmu, Suv420h2, Rgs9bp), and alternative splicing regulators
(e.g., Bicc1, Prpf31, Rbpms) (Dataset S1), which may partially explain
the large-scale transcriptional alterations observed.
The fructose signatures showed strong tissue-speciﬁcity, with 664
genes unique to the hypothalamus, 136 unique to the hippocampus,
and 70 overlapping between tissues. In particular, only in hypothalamus
we observed upregulation of Slc2a5 (encoding themajor fructose trans-
porter GLUT5) and downregulation of Slc2a4 (encoding the glucose
transporter protein GLUT4). The signatures also differ by direction of
change between the two brain compartments: 68% of hypothalamic sig-
natures showed down-regulation compared to 42% in hippocampus.
Among the overlapping genes between the two brain regions (Dataset
S1), only 6 showed consistent upregulation (Atp5f1, Pnpla1, Pomc,
Sepw1, Slc39a12, and Ubc) and 5 showed consistent downregulation
(Alox15, Dstn, Rpl30, Slc39a4, and Slc5a7). The consistent genes are
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inﬂammation, and cognition.
Compared to the fructose group, the DHA+ fructose group showed
differential expression of 651 and 462 genes, 449 and 277 transcripts,
and alternative exon usage for 155 and 81 genes in hypothalamus and
hippocampus at p b 0.01, respectively (Dataset S1), which together de-
ﬁne “DHA gene signatures” of 910 unique genes (382 passed FDR b 5%)
in hypothalamus and 569 unique genes (246passed FDR b 5%) in hippo-
campus. Strikingly, these DHA signatures signiﬁcantly overlapped with
the fructose signatures (Table 1), with DHA reversing the expression of
the common signatures perturbed by fructose in both brain regions
(Fig. 2b; Dataset S1).
3.3. Functional Categorization of Fructose and DHA Transcriptomic
Signatures
We found enrichment of both tissue-speciﬁc and shared biological
pathways between brain regions and between treatment groups (select
pathways shown in Fig. 2d; full details in Dataset S2). Fructose and DHA
signatures shared similar over-represented pathways, although the di-
rection of expression changes of the overlapping genes was predomi-
nantly opposite (exempliﬁed in Fig. 2d insert; details in Dataset S1).
The pathways unique to hypothalamus included those highly relevant
to cardiometabolic, inﬂammatory, and neuronal functions. The pathway
affected in the hippocampuswas “neurological processes”. Those affect-
ed in both regionswere related to extracellularmatrix (ECM), adhesion,
complement, and insulin-like growth factor (IGF) signaling.
3.4. Induction of DNA Methylomic Changes by Fructose and Normalization
by DHA
To identify epigenomic changes which may play a role in the
transcriptomic alternation associated with fructose and DHA, we exam-
ined the DNA methylome using RRBS that measures millions of poten-
tial DNA methylation sites at single base resolution. We found that
fructose consumption induced a large-scale switch of the methylation
patterns in both brain regions: 734 and 810 of differentially methylated
loci (DMLs) showed hypomethylation and hypermethylation in hypo-
thalamus, respectively; 972 and 900 DMLs showed hypomethylation
and hypermethylation in hippocampus at a FDR b 5%, respectively
(Fig. 2c). DHA largely reversed the fructose-induced methylation
changes in these two brain regions (Fig. 2c; Table 1).
3.5. Relationship Between Differential Methylation and Differential
Expression
To explore the potential relationship between DMLs and gene ex-
pression,wemapped the fructose DMLs in each brain region to adjacent
genes within 10 kb distance. We found 50% of DMLs to be located in the
intergenic regions, 34% in the gene body (including 5′-UTR, intron,
coding sequence, and 3′-UTR), and 16% in the upstream or downstream
regions of the genes, with a paucity of DMLs in the promoter and tran-
scription start site (Fig. S1; Table S2). Assessing the methylome-
transcriptome relationship revealed co-localization of DMLs and gene
signatures: 74 out of the 734 (10.1%) hypothalamic signature genes
and 18 out of the 206 (8.7%) hippocampal signature genes co-Fig. 2. Changes in metabolic and behavior phenotypes, transcriptome, DNA methylome, a
(a) Metabolic and behavior phenotypes. From left to right: blood glucose, serum triglycerides,
in the Barnes Maze test. Fructose group was compared with the control group, and the fructo
sided Student's t-test. Error bars in the plots are standard errors. N= 8/group. (b) Heatmap of
low to high expression values. (c) Heatmap of DNA methylation changes in hypothalamus a
biological pathways affected by fructose and DHA in hypothalamus and hippocampus. Bars are
opposite direction of changes in genes in the “focal adhesion” pathway in the hypothalamus b
levels. In the insert plot Y-axis indicates log10 fold changes. The fructose + DHA group is labellocalized with DMLs within 50 kb distance (Table S3), suggesting cis-
regulation of gene expression by the local DMLs. Notably, some of the
genes with co-localizing DMLs are transcription factors (Aff3, Junb, and
Zbtb16) or epigenetic factors (Parp9) (Dataset S3), which could in turn
trans-regulate downstream target genes. Additionally, microRNAs adja-
cent (within 20 kb or 50 kb) to the DMLs had the potential to regulate
36%–45% and 17%–45% of hypothalamic and hippocampal signatures
whichwere the predicted target genes of the correspondingmicroRNAs
(Table S3; details of themicroRNAs in Dataset S3). These results suggest
that fructose-induced DNA methylation changes could contribute
to transcriptional alteration through both cis and trans-regulatory
mechanisms.
3.6. Perturbation of Gene Subnetworks by Fructose and Normalization by
DHA
To explore the gene–gene relations among the fructose signature
genes and to identify key perturbation points of fructose, we employed
two types of networks - protein–protein interaction (PPI) networks
(Keshava Prasad et al., 2009) that capture a majority of the well-
known interactions between proteins, and data-driven Bayesian
networks (BNs) (Zhu et al., 2004, 2008) that elucidate gene–gene regu-
latory relationships (detailed in Materials and Methods). Using these
networks and a network topology-based key driver analysis (KDA),
we identiﬁed multiple candidate key driver (KD) genes whose network
neighboring genes highly overlapped with the fructose signature genes
(Dataset S4). As shown in Fig. 3, the top 5 KDs for each brain region form
central hubs connecting many fructose signature genes in coherent
gene subnetworks, which contained genes involved in diverse process-
es such as the ECM (e.g., Col6a2, Lama4, Thbs1, Fmod, Bgn), small mole-
cule transporters (e.g., Slc6a13, Slc22a2, Slc22a6, Slc13a3), and forkhead
transcription factors (e.g., Foxc2, Foxd2). Between the subnetworks of
the two brain compartments, Fmod, Bgn, and Foxc2 were consistent
KDs revealed from our data-driven approach (Dataset S4). Remarkably,
these KDs and subnetworks were largely reversed by DHA supplemen-
tation (Fig. 3).
3.7. Validation of Bgn and Fmod as Key Regulators ofMetDs and Behavioral
Aberrations in KO Mouse Models
To evaluate our network KD prediction, we used Bgn and Fmod KO
mice (Xu et al., 1998; Svensson et al., 1999) to test the effect of
perturbing these KDs on phenotypes related to MetDs and cognitive
function. Compared to wild type (WT) controls, we observed signiﬁ-
cantly elevated triglyceride, total cholesterol, HDL cholesterol, and un-
esteriﬁed cholesterol in the plasma of both Bgn and Fmod KOmice, sig-
niﬁcant increases in LDL cholesterol in the Bgn KO, and elevated free
fatty acids in the Fmod KO (Fig. 4a). We also found decreased levels of
plasma glucose, insulin, as well as insulin resistance index in Fmod KO
(Fig. 4b–d). The intraperitoneal glucose tolerance test of Bgn KO
demonstrated signiﬁcantly lower plasma glucose at 15 min after
glucose injection and a similar trend in the Fmod KO (Fig. 4e).
To assess the potential inﬂuence of Bgn and Fmod for spatial learning
and memory, we tested the animals in the Barnes Maze. Because Fmod
and Bgn KOs have been previously shown to have impaired tendon
and joints which may affect latency time (Ameye et al., 2002,nd biological pathways in response to fructose treatment and DHA supplementation
serum insulin, insulin resistance index, and latency time in the memory retention probe
se + DHA group was compared to the fructose only group. ⁎p b 0.01 and #p b 0.05 by 2
gene expression changes in hypothalamus and hippocampus. Blue to red colors indicate
nd hippocampus. Blue to red colors indicate low to high methylation levels. (d) Selec
the –log10 enrichment p values of the pathways. The insert plot on the right shows the
etween fructose and DHA: fructose mostly inhibits whereas DHA reverses the expression
ed as F + D in panels b–d..
-
t
Table 1
Overlap between fructose and DHA signatures. Numbers of signiﬁcant genes or methylation loci are shown. Enrichment p value was calculated using 2-sided Fisher's exact test.
Data Tissue Fructose signature DHA signature Overlap Background Fold enrichment p value
RNAseq Hypothalamus 734 910 374 17,435 9.76 7.6E−305
RNAseq Hippocampus 206 569 118 17,411 17.53 1.9E−124
RRBS Hypothalamus 1544 1665 381 6,686,093 984.54 0
RRBS Hippocampus 1872 1957 557 8,742,773 1329.25 0
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data by number of mistakes to eliminate the potential confound origi-
nated by differences in mobility. In addition, number of mistakes has
been demonstrated as a more accurate measure of cognitive abilities
in mice (O'leary and Brown, 2013). During the learning phase, there
was a signiﬁcant effect of animal type (F2,35 = 10.14; p = 0.0003 by
2-way ANOVA) and day (F3,105 = 40.44; p b 0.0001 by 2-way ANOVA)
on the number of mistakes made in the Barnes Maze (Fig. 4f). Post
hoc analysis revealed that both Bgn KO and Fmod KO made fewer
mistakes compared with WT during the learning and the memory
phases. Representative track plot analysis show a difference in strat-
egy to ﬁnd the escape hole (Fig. 4g, inset): the WT animals use a trial
and error approach while the Bgn and Fmod KO animals follow a
more direct path.
3.8. Relevance of Fructose Signatures and KDs to Human Diseases
To assess the relevance of our nutrigenomic signals from the rodent
models to human pathophysiology, we compared the fructose signature
genes as well as the KDs to human GWAS of MetDs and brain related
diseases or traits.We found numerous overlapping genes between fruc-
tose signature genes and top GWAS hits in the GWAS catalog for a broad
range of brain disorders and MetDs-related diseases or traits (Dataset
S4). Importantly, KDs such as Fmod, Col1a2, Col18a1, and Dcn were
GWAS candidate genes associatingwith obesity, cardiovascular disease,
metabolic syndrome, and brainmorphology and cognition, respectively.
When using full sets of GWAS results we had accessed for plasma lipids,
T2D, systolic and diastolic blood pressure traits, cognitive traits, and bi-
polar disorder, we found that human orthologs of the fructose signature
genes derived from both hypothalamus and the hippocampus were sig-
niﬁcantly enriched for genetic polymorphisms showing stronger associ-
ations with these diseases or traits (Table 2).
4. Discussion
In this systems nutrigenomics study, we show that fructose re-
models fundamental aspects of gene regulation such as differential
DNA methylation, differential gene expression, alternative splicing,
and implications for microRNA alterations, all of which have the poten-
tial to impact pathogenesis. In addition, we found that fructose alters
the organization of genes in brain region-speciﬁc networks interrelating
cell metabolism, immune function, inﬂammation, and cell communica-
tion via key regulators such as the extracellular matrix genes Bgn and
Fmod. Remarkably, we found that DHA supplementation was capable
to reverse the genomic, epigenomic, network, and phenotypic perturba-
tions induced by fructose via the same key drivers.
Our ﬁndings indicate that fructose and DHA induce transcriptomic
reprogramming by engaging core transcription factors, splicing factors,
and epigenetic modiﬁcations. For instance, fructose altered classic
transcription factors such as Tcf7l2 (the most signiﬁcant and robust
signal for T2D from human GWAS) (Voight et al., 2010) and Zbtb16. Ad-
ditionally, N20% of the fructose and DHA signature genes only showed
changes at isoform or alternative splicing levels but not overall expres-
sion, and alternative splicing factors such as Bicc1, Prpf31, and Rbpms
were among the signature genes, supporting the importance of RNA
splicing in the pathogenesis of human diseases highlighted recently
(Xiong et al., 2015). The involvement of epigenetic mechanisms infructose and DHA actions was substantiated by the signiﬁcant alter-
ations in the methylome of hypothalamus and hippocampus. cis-Regu-
lation of transcriptome by DNA methylation was evidenced by co-
localization of a subset of signature genes with local DMLs; trans-
regulation mechanism was supported by the co-localization of DMLs
with a number of transcriptional regulators (e.g., Aff3, Junb, Zbtb16,
and Parp9) and microRNAs (e.g., rno-miR-421, rno-miR-143) whose
predicted target geneswere enriched among the signature genes. An in-
creasing body of evidence indicates that neurological and psychiatric
disorders have an epigenetic component (Jakovcevski and Akbarian,
2012, Tsankova et al., 2007). In particular, disruption in cell metabolism
seems to be a driving force for epigenetic changes associated with cog-
nitive function (Tyagi et al., 2015). The current results showing that
DHA can counteract the broad transcriptomic and methylomic alter-
ations induced by fructose imply that diet has the ability to regulate
the susceptibility to disease by modulating the multifaceted transcrip-
tional machinery.
Our studies also revealed broad impact of fructose and DHA on fun-
damental cell processes encompassing metabolism, inﬂammation, cell
communication, and neuronal signaling, as well as critical differences
between the two brain regions. For instance, the fructose and glucose
transporter genes Slc2a5 and Slc2a4, and a broader category of pathways
including insulin signaling, cardiomyopathy, transforming growth
factor (TGF) beta signaling, mitogen-activated protein kinases (MAPK)
signaling, platelet-derived growth factor (PDGF) signaling, toll like
receptor (TLR) signaling, brain-derived neurotropic factor (BDNF) sig-
naling, neural cell adhesionmolecule (NCAM) signaling, and axon guid-
ance were perturbed only in the hypothalamus. In fact, most of the
hypothalamic pathways have been recently implicated in leptin resis-
tance, hypothalamic deregulation and peripheral metabolism impair-
ment (Milanski et al., 2012, Yan et al., 2014). The prominent response
of the hypothalamus to diets is consistent with its role as the master
metabolic sensor and regulator, and the current results suggest that
these actions intermingle with inﬂammatory and cognitive signals. In
contrast, the effects of fructose on the hippocampus were prominent
in pathways engaged in cognitive function and neurological processes.
For instance, hippocampal signature genes Pdc, Chrnb4, and Gch1 were
previously implicated in schizophrenia (Sullivan et al., 2008), addictive
behavior (Picciotto and Kenny, 2013), attention and vigilance (Yasuda
et al., 2014), and early-onset Parkinson's disease (Cederfjall et al.,
2013). The biological pathways affected in both brain regions were
related to ECM, focal adhesion, complement cascade, smooth muscle
contraction, and IGF signaling, which have been implicated in both
metabolic and brain disorders (Soleman et al., 2013, Frischknecht and
Gundelﬁnger, 2012, Chen et al., 2011, Phieler et al., 2013, Skaper, 2007).
A highlight of the study was the identiﬁcation of the extracellular
matrix genes Bgn and Fmod as key intermediates of the fructose effects
on the gene network and phenotypic alterations, and these ﬁndings
were corroborated in two knockout mouse models. Small leucine-rich
proteoglycans Fmod and Bgn consistently emerged as KDs in both
brain regions for both dietary components, and the expression levels
of both genes were also signiﬁcantly altered by fructose and DHA.
Fmod and Bgn are important structural components of the ECM. The
role of the ECM in the regulation of neurite outgrowth, and neural
functionality and plasticity (Dityatev et al., 2010) as well as metabolic
diseases (Soleman et al., 2013, Frischknecht and Gundelﬁnger, 2012,
Chan et al., 2014) is becoming increasingly recognized. Our study
Fig. 3. Gene subnetworks and top network key drivers (KDs) of fructose and DHA. (a) KDs and gene subnetwork in hypothalamus. (b) KDs and gene subnetwork in hippocampus. Larger
nodes depict KDs; greynodes are network genes in theneighborhoodof KDs that are not affected by fructose or DHA; top andbottomhalves of eachnode, if colored, denotes genes affected
by fructose (top) and DHA (bottom), respectively; red and blue colors denotes increased and decreased expression, respectively. Direction of change for the fructose group is determined
by comparison with the control group; direction of change for the DHA + fructose group is determined by comparison with the fructose group.
163Q. Meng et al. / EBioMedicine 7 (2016) 157–166provides unique nutrigenomic-based evidence that proteoglycans are
likely main orchestrators of important metabolic and cognitive process-
es in the brain.
To assess the translatability of our rodent ﬁndings to human patho-
physiology, we found signiﬁcant intersections between the fructose sig-
natures or the network KDs identiﬁed in our rodentmodels and human
GWAS hits for neurological and neurodegenerative diseases, psychiatricdiseases, and various metabolic diseases. As human GWAS implies a
causal role of the candidate genes based on genetic evidence, the over-
lapping signatures or network KDs in response to fructose likely play
causal roles in the development of MetDs or brain disorders. The same
genes also likely mediate the beneﬁcial actions of DHA.
The strength of our study lies in the use of powerful systems
nutrigenomic approach to comprehensively characterize phenotypic
Fig. 4. Phenotypic validation of Bgn and Fmod using knockout (KO) mice. (a) Lipid traits including triglyceride (TG), total cholesterol, HDL cholesterol, un-esteriﬁed cholesterol (UC), LDL
cholesterol and free fatty acids (FFA). (b) Glucose. (c) Insulin. (d) Insulin resistance (IR) measured by insulin sensitivity index. (e) Intraperitoneal glucose tolerance test (IPGTT).
(f) Mistakes made during the Barnes Maze test in four days of the learning phase. (g) Track plots and mistakes made during Barnes Maze test for spatial memory. Two-sided Student's
t-test was used to test statistical difference between knockout mice (Bgn KO or Fmod KO) and wild-type (WT) mice for analyses in (a)–(g). Two-way ANOVA with Holm-Sidak post
hoc analysis for multiple comparisons was performed for the learning curves in panel (f) with *WT vs. Bgn KO; #Bgn KO vs. Fmod KO; and †WT vs. Fmod KO. Error bars in the plots are
standard errors. ⁎p b 0.05. Sample size n = 8–16.
164 Q. Meng et al. / EBioMedicine 7 (2016) 157–166andmulti-tissue transcriptomic andmethylomic proﬁles of fructose and
DHA, followed bynetworkmodeling, in vivo validation, and humandata
integration. The highly integrative nature not only enables a compre-
hensive and in-depth exploration of themolecularmechanismsmediat-
ing the actions of nutrition on health and disease, but also pinpoints
critical regulators of the biological pathways and provides compellingTable 2
Enrichment of humanGWAS signals in fructose signatures andKDs by SNP set enrichment
analysis (SSEA).
Tissue GWAS
disease/trait
GWAS
studya
p-Value
(KS test)b
p-Value
(Fisher's
exact testb
Hypothalamus HDL cholesterol GLGC 4.35E−05 1.25E−12
LDL cholesterol GLGC 1.05E−03 1.90E−05
Total cholesterol GLGC 8.51E−06 3.65E−14
Triglycerides GLGC 5.88E−04 3.09E−09
Diastolic blood pressure ICBP 2.40E−05 7.55E−05
Systolic blood pressure ICBP 3.06E−03 1.16E−02
Type 2 diabetes DIAGRAM+ 2.07E−02 3.39E−02
Cognitive function FHS 1.78E−02 3.18E−03
Bipolar disorder WTCCC 3.06E−02 4.04E−02
Hippocampus HDL cholesterol GLGC 6.48E−05 2.02E−07
LDL cholesterol GLGC 2.98E−05 2.16E−04
Total cholesterol GLGC 2.37E−05 4.19E−13
Triglycerides GLGC 1.34E−02 6.55E−06
Diastolic blood pressure ICBP 4.52E−01 4.59E−03
Cognitive function FHS 9.43E−03 4.28E−02
Schizophrenia CATIE 2.26E−02 3.02E−01
a GLGC: Global Lipids Genetics Consortium; ICBP: The International Consortium for
Blood Pressure; DIAGRAM+: The Diabetes Genetics Replication And Meta-analysis
Consortium; FHS: Framingham Heart Study; WTCCC: Wellcome Trust Case Control
Consortium; CATIE: Clinical Antipsychotic Trials for Intervention Effectiveness.
b Bolded p values are those passed Bonferroni-corrected p b 0.05.evidence for the potential causal role of the identiﬁed genes and
pathways in human diseases.
We note the following limitations of the current study. First, the Bgn
and Fmod KO animals used are not brain-speciﬁc. It is possible that the
phenotypic changes in peripheralmetabolismobserved in thesemodels
are the results of perturbations of these genes outside of the brain.
Future tissue-speciﬁc studies are warranted to further investigate the
action sites of these ECM genes. Second, the behavioral changes ob-
served in our systemic treatment studies of fructose and DHA as well
as in the genetically modiﬁed animal models of Bgn and Fmod could
be inﬂuenced by numerous variables that are either not investigated
or difﬁcult to tease out. Third, we only focused on two brain regions in
the current study and future investigations of additional tissues and
cell types are warranted.
The staggering increase in the prevalence of MetDs, its negative im-
pact on brain function and pathogenesis of brain disorders, and the role
played by fructose consumption as a dietary perturbation in these pro-
cesses are becoming major concerns for public health and basic and
clinical science. Our study provides molecular evidence supporting the
ability of fructose to disrupt critical genes and fundamental physiologi-
cal processes such as insulin, IGF, TLR, TGF beta, BDNF, MAPK, NCAM,
and PDGF signaling pathways and neurological processes. The majority
of these pathways have been implicated in both MetDs and brain disor-
ders. In addition, genes affected by fructose signiﬁcantly overlapped
with human GWAS genes for brain disorders (e.g., Alzheimer's disease,
attention deﬁcient hyperactive disorder, depression, addiction,
Parkinson's disease) and MetDs-related diseases (e.g., blood pressure,
cardiovascular disease, lipids, obesity, metabolic syndrome, and T2D).
Our results point to the capacity of fructose to reprogram molecular
substrates underlying pathology. The remarkable capacity of DHA sup-
plementation to restore genomic, epigenomic, pathway, network, and
phenotypic traits vulnerable to the effects of fructose provides multi-
165Q. Meng et al. / EBioMedicine 7 (2016) 157–166level support for the potential of omega-3 fatty acids as a nutritional
remedy for metabolic and brain dysregulation. This points to an effec-
tive means to guide personalized medicine by matching the disease-
promoting molecular signatures with an agent capable of reversing
the patterns.
In summary, we show that DHA reverses biological pathways and
gene networks perturbed by fructose via transcriptional regulators
(such as transcription factors, epigenetic regulators, splicing factors)
and essential network regulators (such as Bgn and Fmod) that may con-
trol the balance between health and disease. Our study reveals critical
information supporting an action of ECM in orchestrating brain function
through gene network organizations. Our experimental validation high-
lights the predictive power of our systems genomics approaches in
identifying vulnerable disease genes and mechanisms. In addition, our
paradigm based on the integration between rodent studies and
human GWAS serves as a precedent to apply nutrigenomics principles
to predict disease susceptibility and to guide personalized medicine.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.04.008.
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